Quick FactsThere are 425,000 MDR-TB cases a year worldwide, mostly in China, India, and former Soviet Union
Board of Directors
Carol A. Nacy, Ph.D.
Co-Founder, Chief Executive Officer, Chairman of the Board of Directors
Dr. Nacy co-founded our company in 1997 and has served as our CEO and Chairman of the Board since 1999. Prior to Sequella, Dr. Nacy served during 1997 and 1998 as Chief Scientific Officer (CSO) for Anergen, Inc. (NASDAQ: ANRG), a California company acquired by Corixa Corporation in December 1998. From 1993 through 1997, Dr. Nacy was Executive Vice President and CSO at EntreMed, Inc. (NASDAQ: ENMD) and participated in its successful initial public offering in June 1996. Previously, Dr. Nacy was Career Scientist (GS-15) at the Walter Reed Army Institute of Research, Washington, DC. Dr. Nacy currently serves on board of directors of companies and non-profit agencies.
Leo Einck, Ph.D.
Co-Founder, Director, and Chief Scientific Officer
Dr. Einck, a co-founder of our company, joined Sequella as President in 1998. He started and managed several biotechnology companies, including Director of Sponsored Research, Vice-President for Extramural Programs, and then the Vice President for Research Operations at EntreMed (NASDAQ: ENMD) from 1993-1998 and Chief Operating Officer of HemispheRx Biopharma (NYSE: HEB, 1985-1993). Prior to his business experience, Dr. Einck was a molecular biologist at the National Cancer Institute of the NIH.
Mr. Rotter has been a public and private venture investor in telecommunications, aeronautics, and biotechnology for over 25 years and has experience as Chairman of a publicly traded Venture Firm. He was on the Board of AirPatrol Corporation, President and then CEO of MR3 Systems, Inc. He is a graduate of West Point and is active in local politics in California.
John H. Friedman, J.D.
John H. Friedman is the Founding and Managing Partner of Easton Capital Investment Group. Prior to founding Easton Capital, John was the founder and Managing General Partner of Security Pacific Capital Investors, a Managing Director and Partner at E.M. Warburg, Pincus & Co., Inc., and an attorney with Sullivan and Cromwell. Mr. Friedman currently serves on the Boards of Promedior, Experimed, Trellis Bioscience, iTherX, Cardiovascular Systems, and PlaySpan. He was co-chairman of the President's Council at the Cold Spring Harbor Laboratory and serves as a Trustee of The New Museum of Contemporary Art.
Ronald Meltzer, Ph.D., J.D.
Dr. Meltzer has served on our Board of Directors since 1999. Dr. Meltzer was a Distinguished Professor of Political Science specializing in north-south (developed nation to underdeveloped nation) product trade at the State University of New York, Buffalo, for 15 years prior to attending law school. He is currently at the law firm of Wilmer, Cutler & Pickering in Washington, DC.
Paige MacDonald, CPA
Ms. MacDonald is currently CEO of The Highland Group, a real estate development corporation in Montana. From 2002-2005, she was acting CEO and COO of Aeras Global TB Vaccine Foundation, a non-profit funded by the Bill and Melinda Gates Foundation; from 1998-2002 she expanded the retail furniture store, French Country Living, and developed a highly successful retail catalog marketing strategy; from 1975 to 1997 she was COO of the World Wildlife Fund (U.S.) and World Wildlife Foundation. She started her career as a CPA for Price Waterhouse Coopers.
Mr. Miller serves as nonvoting member and secretary of the Board of Directors of the Company. He is also the Corporate Attorney for the Company and has been instrumental in its organization and development of its structure. Mr. Miller has been a Partner in the law firm Grossberg, Yochelson, Fox, & Beyda, in Washington D.C., for more than thirty years. A significant portion of his practice has been devoted to corporate law as it relates to healthcare organizations.
Mr. Hopkins is currently a partner in Resolution Counsel, LLP, a Boston, MA, organization he co-founded to assist in the resolution of disputes between corporate entities. Mr. Hoskins was Vice President, Secretary, and General Counsel for the North American operations of Marion, Marion Merrill Dow, and Hoeschst Marion Roussel (now Aventis), where he helped create corporate partnerships of his organizations with a variety of small and large pharmaceutical companies and organized the acquisition of equity interests in a number of companies. He is a Director of the American Arbitration Association.